Recently, the American biotechnology company Generate:Biomedicines announced that its first AI-designed antibody drug, GB-0895, has officially initiated two Phase III clinical trials. This marks a critical turning point for AI-driven drug development, transitioning from proof-of-concept to tangible product realization.
GB-0895 is a long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), specifically developed for the treatment of severe asthma patients inadequately controlled by existing therapies. Unlike traditional drugs, this antibody was designed through Generate's "Generative Biology Platform," which integrates machine learning models with high-throughput experimental technologies. This approach achieved three major breakthroughs: ultra-high affinity binding to TSLP, an extended half-life, and high specificity.
TSLP, as a key upstream cytokine in multiple inflammatory cascades, plays a central role in allergic diseases such as asthma and atopic dermatitis. Currently, only one TSLP antibody, Tezepelumab (developed by Amgen/AstraZeneca), is approved globally, but it requires monthly injections. In contrast, GB-0895, optimized through AI, extends the dosing interval to once every six months, significantly reducing the treatment burden for patients. Phase I trial data showed that the drug was well-tolerated across doses ranging from 10 to 1200 mg, with a half-life of approximately 89 days and sustained reductions in key biomarker levels, fully supporting the efficacy and safety of the six-month dosing regimen.
Generate's CEO, Mike Nally, emphasized, "Without generative AI, we would only be entering Phase I clinical trials now." This statement aptly summarizes the revolutionary acceleration brought by AI technology—from the initial synthesis of the molecule in 2021 to the initiation of Phase III trials in 2025, GB-0895 completed a journey that traditionally takes over a decade in just four years.
The recently launched SOLAIRIA program includes two global, randomized, double-blind, placebo-controlled Phase III clinical trials—SOLAIRIA-1 and SOLAIRIA-2. The trials plan to enroll approximately 1,600 adult and adolescent patients with severe asthma across more than 40 countries in North America, Europe, Latin America, and the Asia-Pacific region.
The success of GB-0895 is no coincidence but stems from Generate's revolutionary technological foundation. Since its inception in 2020 as an incubated venture by the top-tier investment firm Flagship Pioneering, the company has raised nearly $7 billion, including a $273 million Series C funding round in September 2023. Its core asset is the integrated system known as the "Generate Platform," which achieves end-to-end automation—from sequence design to functional validation—through iterative cycles of computational generation, experimental validation, and data feedback.
Partial Pipeline of Generate Company
Image source: Yaozhi Data - Global Drug Analysis System
Despite its promising prospects, GB-0895 still needs to overcome the rigorous challenges of Phase III clinical trials. The study, involving 1,600 patients, must deliver robust efficacy and safety data—especially given that Phase II was skipped—as any unexpected outcomes could impact regulatory approval. Additionally, the drug is simultaneously being evaluated in Phase I trials for chronic obstructive pulmonary disease (COPD), indicating significant potential for future indication expansion.
References:
1.Yaozh Data - Global Drug Analysis System
2.https://www.prnewswire.com/news-releases/generatebiomedicines-to-initiate-global-phase-3-studies-of-gb-0895-a-long-acting-anti-tslp-antibody-for-severe-asthma-engineered-with-ai-302628189.html